Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Form 8.5 (EPT/RI)-Alliance Pharma plc

13 Jan 2025 09:02

Form 8.5 (EPT/RI)-Alliance Pharma plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Investec Bank plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeAlliance Pharma plc
(c) Name of the party to the offer with which exempt principal trader is connected:Investec is financial advisor to Aegros Bidco Limited (a newly incorporated company indirectly owned by DBAY Affiliates and the ERES IV Fund)
(d) Date dealing undertaken:10th January 2024
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A”N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid/receivedLowest price per unit paid/received
Ordinary sharesPurchases3,631,97261.260.8
Ordinary sharesSales3,679,32061.361

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
N/AN/AN/AN/AN/A

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
N/AN/AN/AN/AN/AN/AN/AN/A

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
N/AN/AN/AN/AN/A

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
N/AN/AN/AN/A

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure:13th January 2025
Contact name:Priyali Bhattacharjee
Telephone number:+91 9768034903

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
21st Aug 20158:45 amRNSExercise of Share Options
17th Aug 20157:00 amRNSNotification of Interim Results
13th Jul 20157:00 amRNSPre-Close Trading Update
10th Jul 20157:00 amRNSAppointment of Finance Director
23rd Jun 20151:30 pmRNSDirector Shareholding
17th Jun 20155:30 pmRNSDirector Shareholding
1st Jun 20153:30 pmRNSExercise of Share Options
27th May 20152:00 pmRNSShare Options
27th May 20157:00 amRNSAGM Statement
20th Apr 20157:00 amRNSHardman & Co issues research report
15th Apr 20157:00 amRNSExercise of Share Options
10th Apr 20157:00 amRNSAnnual Report and AGM Notice
25th Mar 20157:00 amRNSPreliminary Results
3rd Mar 20159:30 amRNSExercise of Share Options
17th Feb 20157:00 amRNSDirectorate Change
16th Feb 20157:00 amRNSNotification of Preliminary Results
2nd Feb 201512:15 pmRNSAcquisition of MacuVision
26th Jan 20157:00 amRNSAppointment of Non-Executive Director
19th Jan 20157:00 amRNSPre-Close Trading Update
18th Dec 20143:27 pmRNSDirectorate Change
10th Sep 20147:00 amRNSAlliance Pharma PLC Interim Results
5th Aug 20147:00 amRNSNotification of Interim Results
9th Jul 20147:00 amRNSPre-Close Trading Update
19th Jun 20145:35 pmRNSExercise of Share Options
21st May 20147:00 amRNSAGM Statement
11th Apr 20142:30 pmRNSShare Options
11th Apr 20147:00 amRNSMajor Interest in Shares
10th Apr 20142:57 pmRNSExercise of Share Options
10th Apr 20147:00 amRNSAnnual Report and Notice of AGM
7th Apr 20142:45 pmRNSTR-1: Notification of Major Interest in Shares
1st Apr 20147:00 amRNSAppointment of Non-Executive Director
26th Mar 20147:00 amRNSPreliminary Results
4th Feb 20147:00 amRNSNotification of Preliminary Results
23rd Jan 20149:30 amRNSTR-1: Notification of Major Interest in Shares
20th Jan 20147:00 amRNSDirector Shareholding
14th Jan 20147:00 amRNSAcquisition in Germany
14th Jan 20147:00 amRNSPre-Close Trading Update
30th Dec 20132:00 pmRNSDirectorate Change
19th Dec 20132:45 pmRNSCULS Conversion and Additional Listing
18th Dec 20137:00 amRNSAcquisition of Lypsyl
9th Dec 20137:00 amRNSMajor Interest in Shares
2nd Dec 20136:00 pmRNSCULS Conversion and Additional Listing
11th Nov 20134:20 pmRNSCULS Conversion and Additional Listing
7th Nov 20131:46 pmRNSCompulsory Conversion of CULS
28th Oct 20133:01 pmRNSCULS Conversion and Additional Listing
25th Oct 20138:00 amRNSMajor Interest in Shares
24th Oct 20135:55 pmRNSShare Options
22nd Oct 20139:30 amRNSCULS Conversion and Additional Listing
11th Oct 20137:00 amRNS£55 Million Bank Facilities
16th Sep 20132:01 pmRNSCULS Conversion and Additional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.